Xeloda and Bevacizumab to Treat Rectal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

June 30, 2011

Study Completion Date

February 28, 2015

Conditions
Rectal Cancer
Interventions
BIOLOGICAL

Bevacizumab

Bevacizumab 4 cycles each 15 days, the first 10 mg/kg and the rest of cycles with 5 mg/kg.

DRUG

capecitabine (Xeloda)

Capecitabine 900 mg/m2 two times a day concomitant during radiotherapy period

RADIATION

Rectal Radiotherapy

Radiotherapy in rectum 45 Gy starting on Bevacizumab 2nd cycle during 5 weeks, 1.8 Gy per day, 5 days at week.

Trial Locations (1)

08907

Institut Català d'Oncologia-L'Hospitalet, L'Hospitalet Del Llobregat

All Listed Sponsors
collaborator

Hoffmann-La Roche

INDUSTRY

lead

Institut Català d'Oncologia

OTHER

NCT00847119 - Xeloda and Bevacizumab to Treat Rectal Cancer | Biotech Hunter | Biotech Hunter